Advance of HLA-B Alleles and Sever Cutaneous Advers Drug Reactions

Resent literatures have reported genetic associations between polymorphisms of human leukocyte antigen B(HLA-B) alleles and severe cutaneous adverse drug reactions(SCADR). The review addressed the advance of relationship between HLA-B*1502 with carbamazepine, HLA-B*5801 with allopurinol, HLA-B*5701 with abacavir. The genetic association of HLA-B and SCADR is ethnicity specific and district restriction. HLA-B*1502 could be a valuable specific biomarker in preventing carbamazepine-induced SJS/TEN in south-east Asian countries.